Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 216

1.

Use of Ex Vivo Patient-Derived Tumor Organotypic Spheroids to Identify Combination Therapies for HER2 Mutant Non-Small Cell Lung Cancer.

Ivanova E, Kuraguchi M, Xu M, Portell AJ, Taus L, Diala I, Lalani AS, Choi J, Chambers ES, Li S, Liu S, Chen T, Barbie TU, Oxnard GR, Haworth JJ, Wong KK, Dahlberg SE, Aref AA, Barbie DA, Bahcall M, Paweletz CP, Jänne PA.

Clin Cancer Res. 2020 Feb 7. doi: 10.1158/1078-0432.CCR-19-1844. [Epub ahead of print]

PMID:
32034078
2.

A State-of-the-Science Review of Arsenic's Effects on Glucose Homeostasis in Experimental Models.

Castriota F, Rieswijk L, Dahlberg S, La Merrill MA, Steinmaus C, Smith MT, Wang JC.

Environ Health Perspect. 2020 Jan;128(1):16001. doi: 10.1289/EHP4517. Epub 2020 Jan 3.

3.

Reply to N. Hanna et al and L. Xie et al.

Ramalingam SS, Dahlberg SE.

J Clin Oncol. 2020 Mar 1;38(7):771-772. doi: 10.1200/JCO.19.02741. Epub 2020 Jan 2. No abstract available.

PMID:
31895616
4.

Harmonization of Tumor Mutational Burden Quantification and Association With Response to Immune Checkpoint Blockade in Non-Small-Cell Lung Cancer.

Vokes NI, Liu D, Ricciuti B, Jimenez-Aguilar E, Rizvi H, Dietlein F, He MX, Margolis CA, Elmarakeby HA, Girshman J, Adeni A, Sanchez-Vega F, Schultz N, Dahlberg S, Zehir A, Jänne PA, Nishino M, Umeton R, Sholl LM, Van Allen EM, Hellmann MD, Awad MM.

JCO Precis Oncol. 2019;3. doi: 10.1200/PO.19.00171. Epub 2019 Nov 12.

5.

Radiologic Considerations and Standardization of Malignant Pleural Mesothelioma Imaging Within Clinical Trials: Consensus Statement from the NCI Thoracic Malignancy Steering Committee - International Association for the Study of Lung Cancer - Mesothelioma Applied Research Foundation Clinical Trials Planning Meeting.

Gill RR, Tsao AS, Kindler HL, Richards WG, Armato SG 3rd, Francis RJ, Gomez DR, Dahlberg S, Rimner A, Simone CB 2nd, de Perrot M, Blumenthal G, Adjei AA, Bueno R, Harpole DH Jr, Hesdorffer M, Hirsch FR, Pass HI, Yorke E, Rosenzweig K, Burt B, Fennell DA, Lindwasser W, Malik S, Peikert T, Mansfield AS, Salgia R, Yang H, Rusch VW, Nowak AK.

J Thorac Oncol. 2019 Oct;14(10):1718-1731. doi: 10.1016/j.jtho.2019.08.012. Epub 2019 Aug 27.

PMID:
31470129
6.

Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression.

Aguilar EJ, Ricciuti B, Gainor JF, Kehl KL, Kravets S, Dahlberg S, Nishino M, Sholl LM, Adeni A, Subegdjo S, Khosrowjerdi S, Peterson RM, Digumarthy S, Liu C, Sauter J, Rizvi H, Arbour KC, Carter BW, Heymach JV, Altan M, Hellmann MD, Awad MM.

Ann Oncol. 2019 Oct 1;30(10):1653-1659. doi: 10.1093/annonc/mdz288.

PMID:
31435660
7.

Pemetrexed, Bevacizumab, or the Combination As Maintenance Therapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer: ECOG-ACRIN 5508.

Ramalingam SS, Dahlberg SE, Belani CP, Saltzman JN, Pennell NA, Nambudiri GS, McCann JC, Winegarden JD, Kassem MA, Mohamed MK, Rothman JM, Lyss AP, Horn L, Stinchcombe TE, Schiller JH.

J Clin Oncol. 2019 Sep 10;37(26):2360-2367. doi: 10.1200/JCO.19.01006. Epub 2019 Jul 30.

8.

Immune Checkpoint Inhibitor Outcomes for Patients With Non-Small-Cell Lung Cancer Receiving Baseline Corticosteroids for Palliative Versus Nonpalliative Indications.

Ricciuti B, Dahlberg SE, Adeni A, Sholl LM, Nishino M, Awad MM.

J Clin Oncol. 2019 Aug 1;37(22):1927-1934. doi: 10.1200/JCO.19.00189. Epub 2019 Jun 17.

PMID:
31206316
9.

Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis.

Awad MM, Leonardi GC, Kravets S, Dahlberg SE, Drilon A, Noonan SA, Camidge DR, Ou SI, Costa DB, Gadgeel SM, Steuer CE, Forde PM, Zhu VW, Fukuda Y, Clark JW, Jänne PA, Mok T, Sholl LM, Heist RS.

Lung Cancer. 2019 Jul;133:96-102. doi: 10.1016/j.lungcan.2019.05.011. Epub 2019 May 11.

PMID:
31200835
10.

Single and Dual Targeting of Mutant EGFR with an Allosteric Inhibitor.

To C, Jang J, Chen T, Park E, Mushajiang M, De Clercq DJH, Xu M, Wang S, Cameron MD, Heppner DE, Shin BH, Gero TW, Yang A, Dahlberg SE, Wong KK, Eck MJ, Gray NS, Jänne PA.

Cancer Discov. 2019 Jul;9(7):926-943. doi: 10.1158/2159-8290.CD-18-0903. Epub 2019 May 15.

PMID:
31092401
11.

Retrospective fractional dose reduction in Tc-99m cardiac perfusion SPECT/CT patients: A human and model observer study.

Pretorius PH, Ramon AJ, King MA, Konik A, Dahlberg ST, Parker MW, Botkin NF, Johnson KL, Yang Y, Wernick MN.

J Nucl Cardiol. 2019 May 10. doi: 10.1007/s12350-019-01743-7. [Epub ahead of print]

PMID:
31077073
12.

Tumor Volume Analysis as a Predictive Marker for Prolonged Survival in Anaplastic Lymphoma Kinase-rearranged Advanced Non-Small Cell Lung Cancer Patients Treated With Crizotinib.

Hida T, Dahlberg SE, Lydon CA, Hatabu H, Johnson BE, Awad MM, Nishino M.

J Thorac Imaging. 2020 Mar;35(2):101-107. doi: 10.1097/RTI.0000000000000413.

PMID:
30985604
13.

Interstitial lung abnormality in stage IV non-small cell lung cancer: A validation study for the association with poor clinical outcome.

Araki T, Dahlberg SE, Hida T, Lydon CA, Rabin MS, Hatabu H, Johnson BE, Nishino M.

Eur J Radiol Open. 2019 Mar 29;6:128-131. doi: 10.1016/j.ejro.2019.03.003. eCollection 2019.

14.

Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer.

Ricciuti B, Kravets S, Dahlberg SE, Umeton R, Albayrak A, Subegdjo SJ, Johnson BE, Nishino M, Sholl LM, Awad MM.

J Immunother Cancer. 2019 Mar 28;7(1):87. doi: 10.1186/s40425-019-0572-6.

15.

M1b Disease in the 8th Edition of TNM Staging of Lung Cancer: Pattern of Single Extrathoracic Metastasis and Clinical Outcome.

Park H, Dahlberg SE, Lydon CA, Araki T, Hatabu H, Rabin MS, Johnson BE, Nishino M.

Oncologist. 2019 Aug;24(8):e749-e754. doi: 10.1634/theoncologist.2018-0596. Epub 2019 Jan 29.

16.

Randomized Phase II Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for Extensive-Stage Small-Cell Lung Cancer: ECOG-ACRIN 2511 Study.

Owonikoko TK, Dahlberg SE, Sica GL, Wagner LI, Wade JL 3rd, Srkalovic G, Lash BW, Leach JW, Leal TB, Aggarwal C, Ramalingam SS.

J Clin Oncol. 2019 Jan 20;37(3):222-229. doi: 10.1200/JCO.18.00264. Epub 2018 Dec 5.

17.

Automated image analysis tool for tumor volume growth rate to guide precision cancer therapy: EGFR-mutant non-small-cell lung cancer as a paradigm.

Nishino M, Wakai S, Hida T, Dahlberg SE, Ozaki M, Hatabu H, Tachizaki H, Johnson BE.

Eur J Radiol. 2018 Dec;109:68-76. doi: 10.1016/j.ejrad.2018.10.014. Epub 2018 Oct 23.

18.

Start Spreading the News: A Comparative Experiment on the Effects of Populist Communication on Political Engagement in Sixteen European Countries.

Hameleers M, Bos L, Fawzi N, Reinemann C, Andreadis I, Corbu N, Schemer C, Schulz A, Shaefer T, Aalberg T, Axelsson S, Berganza R, Cremonesi C, Dahlberg S, de Vreese CH, Hess A, Kartsounidou E, Kasprowicz D, Matthes J, Negrea-Busuioc E, Ringdal S, Salgado S, Sanders K, Schmuck D, Stromback J, Suiter J, Boomgaarden H, Tenenboim-Weinblatt K, Weiss-Yaniv N.

Int J Press Polit. 2018 Oct;23(4):517-538. doi: 10.1177/1940161218786786. Epub 2018 Aug 2.

19.

Vitamin K deficiency in critical ill patients; a prospective observational study.

Dahlberg S, Schurgers L, Schött U, Kander T.

J Crit Care. 2019 Feb;49:105-109. doi: 10.1016/j.jcrc.2018.10.022. Epub 2018 Oct 28.

PMID:
30415179
20.

Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation.

Tsao AS, Lindwasser OW, Adjei AA, Adusumilli PS, Beyers ML, Blumenthal GM, Bueno R, Burt BM, Carbone M, Dahlberg SE, de Perrot M, Fennell DA, Friedberg J, Gill RR, Gomez DR, Harpole DH Jr, Hassan R, Hesdorffer M, Hirsch FR, Hmeljak J, Kindler HL, Korn EL, Liu G, Mansfield AS, Nowak AK, Pass HI, Peikert T, Rimner A, Robinson BWS, Rosenzweig KE, Rusch VW, Salgia R, Sepesi B, Simone CB 2nd, Sridhara R, Szlosarek P, Taioli E, Tsao MS, Yang H, Zauderer MG, Malik SM.

J Thorac Oncol. 2018 Nov;13(11):1655-1667. doi: 10.1016/j.jtho.2018.08.2036. Epub 2018 Sep 25.

21.

Biomarker Clinical Trials in Lung Cancer: Design, Logistics, Challenges, and Practical Considerations.

Le-Rademacher J, Dahlberg S, Lee JJ, Adjei AA, Mandrekar SJ.

J Thorac Oncol. 2018 Nov;13(11):1625-1637. doi: 10.1016/j.jtho.2018.08.2019. Epub 2018 Sep 4. Review.

22.

Clinical Trials, End Points, and Statistics-Measuring and Comparing Cancer Treatments in Practice.

West H, Dahlberg S.

JAMA Oncol. 2018 Dec 1;4(12):1798. doi: 10.1001/jamaoncol.2018.3708. No abstract available.

PMID:
30193254
23.

Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib.

Oxnard GR, Hu Y, Mileham KF, Husain H, Costa DB, Tracy P, Feeney N, Sholl LM, Dahlberg SE, Redig AJ, Kwiatkowski DJ, Rabin MS, Paweletz CP, Thress KS, Jänne PA.

JAMA Oncol. 2018 Nov 1;4(11):1527-1534. doi: 10.1001/jamaoncol.2018.2969.

24.

Pragmatic approaches to address expansion cohort design.

Dahlberg SE, Gray RJ.

Cancer. 2018 Aug;124(16):3290-3292. doi: 10.1002/cncr.31574. Epub 2018 Jul 5. No abstract available.

25.

Indexed Left Atrial Adipose Tissue Area Is Associated With Severity of Atrial Fibrillation and Atrial Fibrillation Recurrence Among Patients Undergoing Catheter Ablation.

Sanghai SR, Sardana M, Hansra B, Lessard DM, Dahlberg ST, Aurigemma GP, Fitzgibbons TP, McManus DD.

Front Cardiovasc Med. 2018 Jun 19;5:76. doi: 10.3389/fcvm.2018.00076. eCollection 2018.

26.

Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune Disorders.

Leonardi GC, Gainor JF, Altan M, Kravets S, Dahlberg SE, Gedmintas L, Azimi R, Rizvi H, Riess JW, Hellmann MD, Awad MM.

J Clin Oncol. 2018 Jul 1;36(19):1905-1912. doi: 10.1200/JCO.2017.77.0305. Epub 2018 May 10.

27.

Interpretation of Results from Under-accruing Studies.

Kravets S, Dahlberg SE.

Oncologist. 2018 Jul;23(7):755-756. doi: 10.1634/theoncologist.2018-0145. Epub 2018 May 8. No abstract available.

28.

Evaluation of End Points in Cancer Clinical Trials.

Yin J, Dahlberg SE, Mandrekar SJ.

J Thorac Oncol. 2018 Jun;13(6):745-747. doi: 10.1016/j.jtho.2018.04.004. Epub 2018 Apr 26. No abstract available.

29.

Social and behavioral factors associated with failing second-line ART - results from a cohort study at the Themba Lethu Clinic, Johannesburg, South Africa.

Evans D, Dahlberg S, Berhanu R, Sineke T, Govathson C, Jonker I, Lönnermark E, Fox MP.

AIDS Care. 2018 Jul;30(7):863-870. doi: 10.1080/09540121.2017.1417527. Epub 2018 Feb 21.

PMID:
29463102
30.

Cytologic-histologic correlation of programmed death-ligand 1 immunohistochemistry in lung carcinomas.

Russell-Goldman E, Kravets S, Dahlberg SE, Sholl LM, Vivero M.

Cancer Cytopathol. 2018 Apr;126(4):253-263. doi: 10.1002/cncy.21973. Epub 2018 Feb 5.

31.

Desphospho-Uncarboxylated Matrix-Gla Protein Is Increased Postoperatively in Cardiovascular Risk Patients.

Dahlberg S, Ede J, Schurgers L, Vermeer C, Kander T, Klarin B, Schött U.

Nutrients. 2018 Jan 5;10(1). pii: E46. doi: 10.3390/nu10010046.

32.

Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial.

Wakelee HA, Dahlberg SE, Keller SM, Tester WJ, Gandara DR, Graziano SL, Adjei AA, Leighl NB, Aisner SC, Rothman JM, Patel JD, Sborov MD, McDermott SR, Perez-Soler R, Traynor AM, Butts C, Evans T, Shafqat A, Chapman AE, Kasbari SS, Horn L, Ramalingam SS, Schiller JH; ECOG-ACRIN.

Lancet Oncol. 2017 Dec;18(12):1610-1623. doi: 10.1016/S1470-2045(17)30691-5. Epub 2017 Nov 9.

33.

Vitamin K and cancer.

Dahlberg S, Ede J, Schött U.

Scand J Clin Lab Invest. 2017 Dec;77(8):555-567. doi: 10.1080/00365513.2017.1379090. Epub 2017 Sep 21. Review.

PMID:
28933567
34.

Tumor Response Dynamics of Advanced Non-small Cell Lung Cancer Patients Treated with PD-1 Inhibitors: Imaging Markers for Treatment Outcome.

Nishino M, Dahlberg SE, Adeni AE, Lydon CA, Hatabu H, Jänne PA, Hodi FS, Awad MM.

Clin Cancer Res. 2017 Oct 1;23(19):5737-5744. doi: 10.1158/1078-0432.CCR-17-1434. Epub 2017 Jul 5.

35.

Investigation of the physical effects of respiratory motion compensation in a large population of patients undergoing Tc-99m cardiac perfusion SPECT/CT stress imaging.

Pretorius PH, Johnson KL, Dahlberg ST, King MA.

J Nucl Cardiol. 2020 Feb;27(1):80-95. doi: 10.1007/s12350-017-0890-3. Epub 2017 Apr 21.

PMID:
28432671
36.

Detection of subclinical vitamin K deficiency in neurosurgery with PIVKA-II.

Dahlberg S, Nilsson CU, Kander T, Schött U.

Scand J Clin Lab Invest. 2017 Jul;77(4):267-274. doi: 10.1080/00365513.2017.1303190. Epub 2017 Mar 20.

PMID:
28319421
37.

Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial.

Neal JW, Dahlberg SE, Wakelee HA, Aisner SC, Bowden M, Huang Y, Carbone DP, Gerstner GJ, Lerner RE, Rubin JL, Owonikoko TK, Stella PJ, Steen PD, Khalid AA, Ramalingam SS; ECOG-ACRIN 1512 Investigators.

Lancet Oncol. 2016 Dec;17(12):1661-1671. doi: 10.1016/S1470-2045(16)30561-7. Epub 2016 Nov 4.

38.

Activity of erlotinib when dosed below the maximum tolerated dose for EGFR-mutant lung cancer: Implications for targeted therapy development.

Lampson BL, Nishino M, Dahlberg SE, Paul D, Santos AA, Jänne PA, Oxnard GR.

Cancer. 2016 Nov 15;122(22):3456-3463. doi: 10.1002/cncr.30270. Epub 2016 Aug 15.

39.

Measuring Generalized Trust: An Examination of Question Wording and the Number of Scale Points.

Lundmark S, Gilljam M, Dahlberg S.

Public Opin Q. 2016 Spring;80(1):26-43. Epub 2015 Oct 19.

40.

A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial.

Yanagita M, Redig AJ, Paweletz CP, Dahlberg SE, O'Connell A, Feeney N, Taibi M, Boucher D, Oxnard GR, Johnson BE, Costa DB, Jackman DM, Jänne PA.

Clin Cancer Res. 2016 Dec 15;22(24):6010-6020. Epub 2016 Jun 8.

41.

Vismodegib or cixutumumab in combination with standard chemotherapy for patients with extensive-stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E1508).

Belani CP, Dahlberg SE, Rudin CM, Fleisher M, Chen HX, Takebe N, Velasco MR Jr, Tester WJ, Sturtz K, Hann CL, Shanks JC, Monga M, Ramalingam SS, Schiller JH.

Cancer. 2016 Aug 1;122(15):2371-8. doi: 10.1002/cncr.30062. Epub 2016 May 10.

42.

Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer.

Sacher AG, Paweletz C, Dahlberg SE, Alden RS, O'Connell A, Feeney N, Mach SL, Jänne PA, Oxnard GR.

JAMA Oncol. 2016 Aug 1;2(8):1014-22. doi: 10.1001/jamaoncol.2016.0173. Erratum in: JAMA Oncol. 2016 Aug 1;2(8):1099.

43.

Multicenter Evaluation of Clinical Diagnostic Methods for Detection and Isolation of Campylobacter spp. from Stool.

Fitzgerald C, Patrick M, Gonzalez A, Akin J, Polage CR, Wymore K, Gillim-Ross L, Xavier K, Sadlowski J, Monahan J, Hurd S, Dahlberg S, Jerris R, Watson R, Santovenia M, Mitchell D, Harrison C, Tobin-D'Angelo M, DeMartino M, Pentella M, Razeq J, Leonard C, Jung C, Achong-Bowe R, Evans Y, Jain D, Juni B, Leano F, Robinson T, Smith K, Gittelman RM, Garrigan C, Nachamkin I.

J Clin Microbiol. 2016 May;54(5):1209-15. doi: 10.1128/JCM.01925-15. Epub 2016 Mar 9.

44.

Clinical and Molecular Characteristics of NF1-Mutant Lung Cancer.

Redig AJ, Capelletti M, Dahlberg SE, Sholl LM, Mach S, Fontes C, Shi Y, Chalasani P, Jänne PA.

Clin Cancer Res. 2016 Jul 1;22(13):3148-56. doi: 10.1158/1078-0432.CCR-15-2377. Epub 2016 Feb 9.

45.

Volumetric Tumor Response and Progression in EGFR-mutant NSCLC Patients Treated with Erlotinib or Gefitinib.

Nishino M, Dahlberg SE, Fulton LE, Digumarthy SR, Hatabu H, Johnson BE, Sequist LV.

Acad Radiol. 2016 Mar;23(3):329-36. doi: 10.1016/j.acra.2015.11.005. Epub 2016 Jan 8.

46.

MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression.

Awad MM, Oxnard GR, Jackman DM, Savukoski DO, Hall D, Shivdasani P, Heng JC, Dahlberg SE, Jänne PA, Verma S, Christensen J, Hammerman PS, Sholl LM.

J Clin Oncol. 2016 Mar 1;34(7):721-30. doi: 10.1200/JCO.2015.63.4600. Epub 2016 Jan 4.

PMID:
26729443
47.

Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs.

Lin JJ, Cardarella S, Lydon CA, Dahlberg SE, Jackman DM, Jänne PA, Johnson BE.

J Thorac Oncol. 2016 Apr;11(4):556-65. doi: 10.1016/j.jtho.2015.12.103. Epub 2015 Dec 25.

48.

Association Between Younger Age and Targetable Genomic Alterations and Prognosis in Non-Small-Cell Lung Cancer.

Sacher AG, Dahlberg SE, Heng J, Mach S, Jänne PA, Oxnard GR.

JAMA Oncol. 2016 Mar;2(3):313-20. doi: 10.1001/jamaoncol.2015.4482.

49.

ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer.

Govindan R, Mandrekar SJ, Gerber DE, Oxnard GR, Dahlberg SE, Chaft J, Malik S, Mooney M, Abrams JS, Jänne PA, Gandara DR, Ramalingam SS, Vokes EE.

Clin Cancer Res. 2015 Dec 15;21(24):5439-44. doi: 10.1158/1078-0432.CCR-15-0354. Review.

50.

Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer.

Calles A, Liao X, Sholl LM, Rodig SJ, Freeman GJ, Butaney M, Lydon C, Dahlberg SE, Hodi FS, Oxnard GR, Jackman DM, Jänne PA.

J Thorac Oncol. 2015 Dec;10(12):1726-35. doi: 10.1097/JTO.0000000000000687.

Supplemental Content

Loading ...
Support Center